Chronic Myelomonocytic Leukaemia- Pipeline Insight, 2023

Chronic Myelomonocytic Leukaemia- Pipeline Insight, 2023

DelveInsight’s, “Chronic Myelomonocytic Leukaemia- Pipeline Insight, 2023” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Chronic Myelomonocytic Leukaemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Chronic Myelomonocytic Leukaemia: Understanding

Chronic Myelomonocytic Leukaemia: Overview

Chronic myelomonocytic leukaemia (CMML) is a rare type of blood cancer. CMML generally starts when a stem cell in the bone marrow mutates. This results in abnormal blood cell production and an overproduction of blasts and immature monocytes, types of white blood cells that crowd out other blood cells. The blasts never mature completely into normal monocytes so they can’t carry out their normal functions. The World Health Organisation (WHO) has included CMML in a group of blood cancers called myeloproliferative and myelodysplastic disorders. CMML is a separate condition with different treatment options because people with CMML can have features of both myeloproliferative disorders (MPN) and myelodysplastic disorders (MDS). The exact cause of CMML is not known. However, the common risk factors include old age and show a male predominance. The most common sign of CMML is having too many monocytes in the blood which can settle in the liver and spleen, causing them to enlarge. The disease usually develops slowly and doesn’t cause symptoms at first, however at later stages the symptoms may include bleeding (such as nosebleeds), skin rashes or lumps, and abdominal discomfort) from a swollen spleen among others. There are different types of CMML including:

Type 0 CMML means you have less than 2% blast cells in your blood and less than 5% blast cells in your bone marrow.

Type 1 CMML means you have 2-4% blast cells in your blood or 5-9% blasts in your bone marrow. Some people have both.

Type 2 CMML means you have 5-19% blast cells in your blood and 10-19% in your bone marrow.

Diagnosing CMML usually involves a series of repeated tests, including blood and bone marrow tests. There is no one standard treatment regimen for CMML. Treatment depends on factors including: the stage of the disease; a person’s age; the extent of symptoms; and general overall health. People with MDS-type CMML and MPN-type CMML usually are treated with the same or similar chemotherapy drugs to control the disease. In addition, supportive care therapies such as blood and platelet transfusions, antibiotics may also be used by by increasing blood counts and stopping infections.

""Chronic Myelomonocytic Leukaemia- Pipeline Insight, 2023"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Myelomonocytic Leukaemia pipeline landscape is provided which includes the disease overview and Chronic Myelomonocytic Leukaemia treatment guidelines. The assessment part of the report embraces, in depth Chronic Myelomonocytic Leukaemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Myelomonocytic Leukaemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Myelomonocytic Leukaemia R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Myelomonocytic Leukaemia.

Chronic Myelomonocytic Leukaemia: Emerging Drugs Chapters

This segment of the Chronic Myelomonocytic Leukaemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Myelomonocytic Leukaemia: Emerging Drugs

MBG453: Novartis Pharmaceuticals

Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor expressed on multiple immune cells and on leukemic stem/progenitor cells and blasts, but not on normal hematopoietic stem cells. The drug is in Phase III for the treatment of CMML.

CFI-400945: Treadwell Therapeutics

CFI-400945, an oral, first-in-class selective inhibitor of the serine/threonine kinase PLK4, a cell cycle kinase known to be the master upstream regulatory of centriole duplication and is critical for the maintenance of genomic integrity. The drug is currently in TWT-202, a Phase I/II study to evaluate CFI-400945 Safety, tolerability, and pharmacokinetic and pharmacodynamic profiles as a single agent or in combination with azacitidine or decitabine in patients with CMML.

NMS-088: Nerviano Medical Sciences

NMS-088 is a potent and selective FLT3 inhibitor with strong activity on the F691L resistance mutation to gilteritinib and other FLT3 inhibitors. Based on its activity on CSF1R inhibition it has potential for treatment of CMML, where this receptor is highly expressed. NMS-088 is currently being explored in MKIA-088-001 trial, a multi-center Phase I/II study to evaluate safety, tolerability and efficacy in patients with CMML.

NC525: NextCure, Inc.

NC525 is a monoclonal antibody and specifically binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. The drug is being evaluated in the Phase I for the treatment of CMML.

Further product details are provided in the report……..

Chronic Myelomonocytic Leukaemia: Therapeutic Assessment

This segment of the report provides insights about the different Chronic Myelomonocytic Leukaemia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chronic Myelomonocytic Leukaemia

There are approx. 25+ key companies which are developing the therapies for Chronic Myelomonocytic Leukaemia. The companies which have their Chronic Myelomonocytic Leukaemia drug candidates in the most advanced stage, i.e. phase III include, Novartis Pharmaceuticals.

Phases

DelveInsight’s report covers around 25+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Chronic Myelomonocytic Leukaemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intra-articular

Intraocular

Intrathecal

Intravenous

Ophthalmic

Oral

Parenteral

Subcutaneous

Topical

Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

Oligonucleotide

Peptide

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Myelomonocytic Leukaemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Chronic Myelomonocytic Leukaemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Myelomonocytic Leukaemia drugs.

Chronic Myelomonocytic Leukaemia: Report Insights

Chronic Myelomonocytic Leukaemia Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Chronic Myelomonocytic Leukaemia: Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Chronic Myelomonocytic Leukaemia drugs?

How many Chronic Myelomonocytic Leukaemia drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Myelomonocytic Leukaemia?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Myelomonocytic Leukaemia therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Chronic Myelomonocytic Leukaemia and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Novartis Pharmaceuticals

Treadwell Therapeutics

Nerviano Medical Sciences

NextCure, Inc.

Kahr Medical

Faron Pharmaceuticals Ltd

HUTCHMED

Salarius Pharmaceuticals, Inc.

Newave Pharmaceutical Inc

Immune-Onc Therapeutics, Inc.

Key Products

MBG453

CFI-400945

NMS-088

NC525

DSP107

Bexmarilimab

HMPL-306

SP-2577

LP-108

IO-202